载脂蛋白CⅠ基因多态性与阿托伐他汀调脂疗效的相关性

Correlation between Apolipoprotein CⅠ gene polymorphisms and lipid-lowering efficacy of atorvastatin

目的:观察载脂蛋白CⅠ(ApoCⅠ)基因多态性对低剂量阿托伐他汀调脂疗效的影响。方法:选择高脂血症患者387例,其中94例服用阿托伐他汀10mg,每晚1次;于治疗前及治疗开始后第4、8、12周抽血化验血脂指标。采用聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)方法检测ApoCⅠ基因多态性。结果:387例高脂血症患者中H2等位基因相对频率为31.65%,H1等位基因相对频率为68.35%。服用阿托伐他汀8周后,非H2携带者的低密度脂蛋白胆固醇降低水平明显高于H2携带者(P<0.05),但未发现TC、TG及载脂蛋白B(ApoB)水平降低程度的基因型间差异(P均>0.05)。结论:ApoCⅠ基因多态性对阿托伐他汀的调脂疗效的影响不显著。

AIM：To investigate the effect of polymorphisms in ApoCⅠ gene on the treatment efficacy of small dose of atorvastatin on hyperlipidemia.METHODS：94 cases in 387 patients with hyperlipidemia were treated with oral administration of atorvastatin 10 mg/d.The TC,TG,LDL-C,apoA1 and apoB were measured before treatment and after 4,8,12 weeks of treatment.The polymorphisms of ApoCⅠgene on HpaⅠlocus were determined by using PCR-RFLP method.RESULTS：In 387 patients,the relative frequency of H2 allele and H1 allele were 0.3165 and 0.6835,respectively.After 8 weeks of treatment,the decreasing in level of LDL-C was more prominent in non H2 carriers than that in H2 carriers（P0.05）,but this difference was not found in TC,TG and ApoB.CONCLUSION：The efficacy of lipid-lowering therapy was no difference in Apo CⅠ gene polymorphisms.